About-cancer / lapaʻau / clinical-hoʻokolohua / maʻi / gastrointestinal-neuroendocrine-tumor-g1 / lapaʻau
Hoʻomaʻamaʻa i nā hoʻokolohua lapaʻau no ka Gastrointestinal Neuroendocrine Tumor G1
ʻO nā hoʻokolohua hoʻokolohua kahi noiʻi noiʻi e pili ana i ka poʻe. ʻO nā hoʻokolohua hoʻokolohua ma kēia papa inoa no ka gastrointestinal neuroendocrine tumor g1 lapaʻau. Kākoʻo ʻia nā hoʻokolohua āpau ma ka papa inoa e NCI.
ʻO ka ʻike pili o NCI e pili ana i nā hoʻokolohua hoʻokolohua e wehewehe i nā ʻano a me nā pae o nā hoʻokolohua a pehea e lawe ai. Nānā nā hoʻāʻo hoʻokolohua i nā ala hou e pale ai, ʻike ai, a mālama ai paha i ka maʻi. E makemake paha ʻoe e noʻonoʻo e pili ana i ka lawe ʻana i ka hoʻokolokolo hoʻokolohua. E kamaʻilio me kāu kauka no ke kōkua i ka hoʻoholo ʻana inā kūpono kekahi iā ʻoe.
Nā hoʻāʻo 1-4 o 4
ʻO Cabozantinib S-malate i ka mālama ʻana i nā mea maʻi me nā Tumuna Neuroendocrine i hana mua ʻia me Everolimus i holomua ma kahi o ka wahi, Metastatic, a i ʻole hiki ʻole ke hemo ʻia e ka ʻoki kino.
Ke nānā nei kēia pae III i ka cabozantinib S-malate e ʻike ai i ka maikaʻi o ka hana me ka placebo i ka mālama ʻana i nā mea maʻi me nā tumo neuroendocrine i mālama mua ʻia me everolimus i pālahalaha ʻia i nā mea kokoke a i ʻole nā lymph node, ua hoʻolaha ʻia i nā wahi ʻē aʻe o ke kino, a i ʻole hiki ʻole e hoʻoneʻe ʻia e ka ʻoki kino. ʻO Cabozantinib S-malate kahi lāʻau chemotherapy i ʻike ʻia ma ke ʻano he inhibitor tyrosine kinase, a māka ia i nā kikoʻī kikoʻī tyrosine kinase, i ka wā i ālai ʻia, hiki i ka ulu ulu ulu.
Kahi: 329 mau wahi
PEN-221 ma Somatostatin Receptor 2 e hōʻike nei i nā ʻōkole holomua me ka neuroendocrine a me nā maʻi puʻupuʻu liʻiliʻi liʻiliʻi.
ʻO Protocol PEN-221-001 kahi lepili hamo, multicenter Phase 1 / 2a hoʻopaʻa loiloi iā PEN-221 i nā mea maʻi me SSTR2 e hōʻike ana i ka gastroenteropancreatic holomua (GEP) a i ʻole akemāmā a i ʻole thymus a i ʻole nā tumo neuroendocrine ʻē aʻe a i ʻole ke kanesa maʻi ʻaʻa liʻiliʻi liʻiliʻi a i ʻole ka cell cancer neuroendocrine nui. o ka māmā.
Kahi: 7 mau wahi
ʻO Ribociclib a me Everolimus i ka mālama ʻana i nā mea maʻi me nā Tumo Neuroendocrine Advanced Maikaʻi Maikaʻi o Foregut Origin.
Ke aʻo nei kēia mahele II i ka maikaʻi o ka hana ʻana o ribociclib a me everolimus i ka mālama ʻana i nā mea maʻi me nā tumo neuroendocrine ʻokoʻa o ka foregut origin i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino a ʻaʻole hiki ke hoʻōla ʻia a mālama ʻia paha me ka lāʻau. Hiki paha iā Ribociclib a me everolimus ke hōʻoki i ka ulu ʻana o nā hunaola puʻupuʻu ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 5 mau wahi
ʻO Sapanisertib i ka mālama ʻana i nā maʻi me ka Metastatic a i ʻole Refractory Pancreatic Neuroendocrine Tumor i hiki ʻole ke hemo ʻia e ke ʻoki kino.
Ke aʻo nei kēia pae II i ka maikaʻi o ka sapanisertib e hana ai i ka mālama ʻana i nā mea maʻi me ka tumreatic neuroendocrine tumreatic i pāhola ʻia i nā wahi ʻē aʻe o ke kino (metastatic), ʻaʻole e pane i ka lāʻau lapaʻau (refreory), a i ʻole hiki ʻole ke wehe ʻia. Hiki i nā lāʻau e like me sapanisertib ke hoʻopau i ka ulu ʻana a hōʻemi paha i nā hunaola tumo ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 379 mau wahi
